RxDoctor Payments Data

Trieu Ho, MD

Clinical Cardiac Electrophysiology · Grapevine, TXNPI 1568634681

Payments from drug & device makers

$83,263in general payments, 2019–2025

Across 270 payments — averaging $308.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$51K
  • Johnson & Johnson$29K
  • Medtronic$2K
  • Cardiva Medical, Inc.$488
  • E.r. Squibb & Sons, L.L.C.$280
  • Novartis$122
  • plus $822 from 17 others

What the payments were for

  • Consulting fees$45,10454%
  • Speaking & faculty fees$27,50033%
  • Travel & lodging$3,1044%
  • Food & beverage$7,5529%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,263 in reported general payments places this provider in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$448,417
Medicare patients
571
Services billed
3,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$193,003
XareltoRivaroxaban55$54,800
Flecainide Acetate193$6,571
Amiodarone Hcl166$2,214
SotalolSotalol Hcl101$1,886
Esomeprazole Magnesium22$568
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$527
Metoprolol Succinate47$508
ClopidogrelClopidogrel Bisulfate37$484
Sucralfate14$341
Midodrine Hcl19$304
Doxycycline Monohydrate30$203
Metoprolol Tartrate17$188
Cephalexin18$175
Potassium Chloride12$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$193,003238 claims
Johnson & JohnsonXarelto$28,653$54,80055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Grapevine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →